Carole  Ho net worth and biography

Carole Ho Biography and Net Worth

Carole Ho is our Chief Medical Officer and Head of Development. At Denali, Carole has built an integrated Development organization that is responsible for advancing therapeutic candidates from pre-IND enabling studies through Phase 1 to Phase 3 clinical trials. Under Carole’s leadership, her team has delivered on Denali’s biomarker driven development strategy to enable early target and pathway engagement in the clinic for therapeutics in development for Parkinson’s disease, Alzheimer's disease, and ALS.

Carole previously served as Vice President of Genentech Early Clinical Development and was responsible for delivery of pivotal trial-ready drug candidates in Neurology, Ophthalmology, Immunology, and Infectious Disease. During her 8-year tenure at Genentech, Carole held roles with leadership responsibility across multiple early- and late-stage clinical programs including Rituxan® for Wegener’s granulomatosis and microscopic polyangiitis, ocrelizumab for Multiple Sclerosis, lampalizumab for dry AMD, and crenezumab for Alzheimer’s Disease. At Genentech, in collaboration with Banner Health, Carole's team led the initiation of the world's first prevention trial in Alzheimer's disease in participants at risk for dementia due to a genetic mutation.

Carole completed her residency in Neurology at Harvard Medical School at the Massachusetts General Hospital / Brigham and Women’s Hospital, where she also served as Chief Resident. She obtained her M.D. from Cornell University and S.B. in Biochemical Sciences from Harvard College. Prior to her Industry career, Carole was on Faculty in the Department of Neurology at Stanford University. Carole currently serves on the Board of Directors of Beam Therapeutics.

What is Carole Ho's net worth?

The estimated net worth of Carole Ho is at least $3.53 million as of August 23rd, 2023. Dr. Ho owns 182,809 shares of Denali Therapeutics stock worth more than $3,533,698 as of December 6th. This net worth evaluation does not reflect any other assets that Dr. Ho may own. Additionally, Dr. Ho receives a salary of $737,200.00 as Insider at Denali Therapeutics. Learn More about Carole Ho's net worth.

How old is Carole Ho?

Dr. Ho is currently 50 years old. There are 3 older executives and no younger executives at Denali Therapeutics. The oldest executive at Denali Therapeutics is Dr. Marc Tessier-Lavigne Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director, who is 63 years old. Learn More on Carole Ho's age.

What is Carole Ho's salary?

As the Insider of Denali Therapeutics Inc., Dr. Ho earns $737,200.00 per year. The highest earning executive at Denali Therapeutics is Dr. Ryan J. Watts Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $1,040,000.00 per year. Learn More on Carole Ho's salary.

How do I contact Carole Ho?

The corporate mailing address for Dr. Ho and other Denali Therapeutics executives is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. Denali Therapeutics can also be reached via phone at (615) 866-8548 and via email at [email protected]. Learn More on Carole Ho's contact information.

Has Carole Ho been buying or selling shares of Denali Therapeutics?

Carole Ho has not been actively trading shares of Denali Therapeutics within the last three months. Most recently, Carole Ho sold 2,522 shares of the business's stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $23.22, for a transaction totalling $58,560.84. Following the completion of the sale, the insider now directly owns 182,809 shares of the company's stock, valued at $4,244,824.98. Learn More on Carole Ho's trading history.

Who are Denali Therapeutics' active insiders?

Denali Therapeutics' insider roster includes Carole Ho (Insider), Steve Krognes (CFO), Vicki Sato (Director), David Schenkein (Director), Alexander Schuth (COO), Marc Tessier-Lavigne (Director), and Ryan Watts (CEO). Learn More on Denali Therapeutics' active insiders.

Are insiders buying or selling shares of Denali Therapeutics?

In the last twelve months, insiders at the sold shares 33 times. They sold a total of 149,403 shares worth more than $4,186,979.86. The most recent insider tranaction occured on November, 15th when Director Vicki L Sato sold 1,666 shares worth more than $31,870.58. Insiders at Denali Therapeutics own 7.9% of the company. Learn More about insider trades at Denali Therapeutics.

Information on this page was last updated on 11/15/2023.

Carole Ho Insider Trading History at Denali Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/23/2023Sell2,522$23.22$58,560.84182,809View SEC Filing Icon  
8/21/2023Sell2,478$22.60$56,002.80185,331View SEC Filing Icon  
8/21/2023Sell2,478$22.60$56,002.80185,331View SEC Filing Icon  
8/14/2023Sell2,768$23.79$65,850.72182,809View SEC Filing Icon  
8/10/2023Sell2,857$24.15$68,996.55185,577View SEC Filing Icon  
2/13/2023Sell2,548$30.10$76,694.80184,285View SEC Filing Icon  
2/10/2023Sell818$29.80$24,376.40179,365View SEC Filing Icon  
2/8/2023Sell1,521$30.88$46,968.48180,183View SEC Filing Icon  
1/9/2023Sell1,459$28.48$41,552.32177,454View SEC Filing Icon  
1/6/2023Sell1,451$28.67$41,600.17178,913View SEC Filing Icon  
1/4/2023Sell2,913$28.69$83,573.97175,500View SEC Filing Icon  
8/23/2022Sell2,424$31.98$77,519.52170,663View SEC Filing Icon  
2/11/2022Sell2,918$34.71$101,283.78View SEC Filing Icon  
1/5/2022Sell2,845$44.78$127,399.10View SEC Filing Icon  
12/6/2021Sell1,476$42.52$62,759.52View SEC Filing Icon  
8/23/2021Sell6,143$48.91$300,454.13View SEC Filing Icon  
8/19/2021Sell2,546$49.58$126,230.68View SEC Filing Icon  
3/29/2021Sell2,822$54.62$154,137.64View SEC Filing Icon  
2/11/2021Sell3,156$70.33$221,961.48View SEC Filing Icon  
2/9/2021Sell1,470$74.68$109,779.601,476View SEC Filing Icon  
10/9/2020Sell30,000$41.22$1,236,600.00View SEC Filing Icon  
9/10/2020Sell3,689$31.00$114,359.00View SEC Filing Icon  
12/23/2019Sell3,464$20.01$69,314.64View SEC Filing Icon  
12/19/2019Sell2,566$20.00$51,320.00View SEC Filing Icon  
7/8/2019Sell17,500$20.29$355,075.00View SEC Filing Icon  
6/10/2019Sell17,500$18.78$328,650.00View SEC Filing Icon  
5/10/2019Sell17,500$22.85$399,875.00View SEC Filing Icon  
3/14/2019Sell1,000$25.01$25,010.00View SEC Filing Icon  
10/1/2018Sell17,500$21.72$380,100.00View SEC Filing Icon  
See Full Table

Carole Ho Buying and Selling Activity at Denali Therapeutics

This chart shows Carole Ho's buying and selling at Denali Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Denali Therapeutics Company Overview

Denali Therapeutics logo
Denali Therapeutics Inc., a biopharmaceutical company, developing a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. It pursues new treatments by assessing genetically validated targets, engineering delivery across the blood-brain barrier, and guiding development through biomarkers that demonstrate target and pathway engagement. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; and DNL343 eIF2B Activator program for amyotrophic lateral sclerosis. The company's other programs comprise SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $19.33
Low: $18.46
High: $19.34

50 Day Range

MA: $19.41
Low: $16.20
High: $21.83

2 Week Range

Now: $19.33
Low: $15.45
High: $33.31


210,752 shs

Average Volume

736,659 shs

Market Capitalization

$2.67 billion

P/E Ratio


Dividend Yield